-
Founded in:
1997-10-27 -
Country:
China -
Address:
No. 1, Wangjiashan Road, Qingshanhu Street, Lin'an District, Hangzhou City, Zhejiang Province -
Tax NO.:
91330185253932420N -
Registered Funds:
56.5 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Docetaxel |
Docetaxel is a paclitaxel anti-tumor drug that exerts its anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the production of microtubule bundles that have lost their normal function and the fixation of microtubules, thereby inhibiting cell mitosis. The binding of docetaxel to microtubules does not change the number of protofilaments, which is different from most spindle toxic drugs currently used in clinical practice.
More
Docetaxel is a paclitaxel anti-tumor drug that exerts its anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the production of microtubule bundles that have lost their normal function and the fixation of microtubules, thereby inhibiting cell mitosis. The binding of docetaxel to microtubules does not change the number of protofilaments, which is different from most spindle toxic drugs currently used in clinical practice. |
114977-28-5 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Atenolol |
A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.
More
A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. |
29122-68-7 | 48 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fexofenadine hydrochloride |
An antihistamine with selective peripheral H1 receptor antagonism, inhibiting the release of histamine from peritoneal mast cells, without anticholinergic, α1-adrenergic or β-adrenergic receptor blocking effects, without sedation or other central nervous system effects, and cannot cross the blood-brain barrier.
More
An antihistamine with selective peripheral H1 receptor antagonism, inhibiting the release of histamine from peritoneal mast cells, without anticholinergic, α1-adrenergic or β-adrenergic receptor blocking effects, without sedation or other central nervous system effects, and cannot cross the blood-brain barrier. |
153439-40-8 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fexofenadine hydrochloride |
An antihistamine with selective peripheral H1 receptor antagonism, inhibiting the release of histamine from peritoneal mast cells, without anticholinergic, alpha;1-adrenergic or beta;-adrenergic receptor blocking effects, without sedation or other central nervous system effects, and cannot cross the blood-brain barrier.
More
An antihistamine with selective peripheral H1 receptor antagonism, inhibiting the release of histamine from peritoneal mast cells, without anticholinergic, alpha;1-adrenergic or beta;-adrenergic receptor blocking effects, without sedation or other central nervous system effects, and cannot cross the blood-brain barrier. |
153439-40-8 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Glibenclamide |
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect
More
Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect |
10238-21-8 | 28 | |
| 1，1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization
More
It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization |
15537-72-1 | 55 |